C Diff Drug Development

Jessica R. Allegretti, MD, MPH, spoke with Healio about a study demonstrating the efficacy of SER-109 in preventing recurrent Clostridioides difficile infection, including in patients using acid-suppressing medications.The data, presented at the ACG Annual Meeting, showed that SER-109 (Seres Therapeutics), an oral investigational microbiome therapeutic, reduced recurrent C. difficile infection

In this video, Jessica R. Allegretti, MD, MPH, discussed findings from the PRISM3 trial evaluating an investigational therapeutic for the prevention of recurrent Clostridioides difficile infection.Allegretti, director of the fecal microbiota center at Brigham and Women’s Hospital, presented the trial findings at the ACG Annual Meeting.

In this video, Jessica R. Allegretti, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting that provided an overview of microbiome therapeutics  currently under investigation for Clostridioides difficile infection.During his presentation, Sahil Khanna, MBBS, MS, professor of medicine at the Mayo Clinic in Rochester, Minnesota, showed data on RBX2660 (Rebiotix Inc.),

Chemical engineers have developed a protective coating that helps anaerobic microbes survive the manufacturing process, making it potentially easier to use them to treat gastrointestinal disease.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Acurx Pharmaceuticals Inc. earned a 12-month price target of $12 from analysts at Maxim Group. Coverage was initiated with a BUY rating, and its price target covering the next twelve months. Shares... | December 6, 2021

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).

Bacthera, the joint venture between Chr. Hansen and Lonza, is to team up with Seres Therapeutics to manufacture Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).

Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions, informed by a systems biology high-throughput interrogation of multidimensional omics and whole structural data, coupled wi …

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

Within the local setting of our study, CDI within 12 months post-LT is of low severity, associated with pre-LT antibiotic exposure and longer hospital stay but no survival impact after LT. Rifaximin use pre-LT reduced the risk of CDI post-LT. This article is protected by copyright. All rights reserv …

Clostridioides difficile infection (CDI) is the major identifiable cause of antibiotic-associated diarrhea. The emergence of hypervirulent C. difficile strains has led to increases in both hospital- and community-acquired CDI. Furthermore, CDI relapse from hypervirulent strains can rea …

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Many antibiotics prescribed in the United States are unnecessary or inappropriate. Improved antibiotic stewardship is needed, not only to curb the threat of antibiotic resistance but also to avoid exposing patients to unnecessary risks.

C. difficile is one of the leading causes of hospital-acquired infections. Arrieta-Ortiz et al. report three predictive models (with extensive validations) for dissecting interplay of regulation and metabolism that underlies host-pathogen interactions of C. difficile. The C. difficile interactive web portal provides access to these models, compiled datasets, and algorithms.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).

BASEL, Switzerland & CAMBRIDGE, Mass. & HORSHOLM, Denmark, November 10, 2021--Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI). Under the terms of the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbio

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) were presented at the 9th International C. diff Conference & Health Expo entitled: "Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?" The presentation was made on Novembe

Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).

Researchers evaluated the safety and efficacy of the investigational, microbiota-based, live biotherapeutic RBX2660 for treatment of recurrent C difficile infection.

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI). ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) will be presented at the 9th Annual International C. diff Conference & Health Expo. taking place virtually on November 4-5, 2021.